Ann: Race releases complete cardio-protection data & video, page-122

First 122 Last

Share
Profile

Follow
IndexInvestor

8,630 Posts.

1426

26/04/23

23:47

Post #: 67468903
Share

Originally posted by Jdlc: ↑

*If* that's true (that the low SP is now considered a commercial risk) then I'd be stunned.

The board took a strategic approach of being 'under the radar' (I'm sure I'm not alone in cringing at the very mention of that phrase).

You cannot attempt to hide in the shadows and then complain when people don't notice you.

The Zantrene science story is compelling (to me at least) yet RACE seem to continue to fall over themselves commercially to avoid sharing good news about it.

Here's a very recent example from the last couple of months; the awarding of the Wolf Prize for Chemistry to a scientist that has published an article on the effectiveness of Zantrene (in its guise as 'CS1').

Previous winners of Wolf Prize awards can be described absolute titans of science; they include names such as Stephen Hawking and Roger Penrose.

I'll give that statement the space it deserves....

If we're no longer under the radar (urgh, there it is again) then am I alone in thinking that award and it's relevance to the Zantrene story should be shouted enthusiastically from the hill-tops? Even if the ASX would not approve such an announcement, surely it warrant coverage on the RACE website or in conversational video?

Investors love to see that kind of validation of any product.

Good luck finding another biotech (or any other product outside of biotech) that has so much credible, independent validation of its utility. You literally 'cannot buy that'.

To me Zantrene's independent validation was, and continues to be, a differentiator.

I could point you to an article on the Race website or to a video where they've talked through the significance of Professor Chuan He's award or of the multiple appearances of 'CS1' in peer-reviewed papers .....except there's none; we must whisper it quietly for fear of others finding out and perhaps wanting a piece of the pie (... and growing the SP with every bite).

I realise this post may upset some, so if I'm being unfair or have missed the memo then I'll be the first to acknowledge it - so help me out, what am I missing?

Expand

The under the radar overseas strategy is a very minor factor in the low SP. And there never was any under the radar strategy within Australia.

By far the main cause of the low SP is that the spectacular results from the open.label Australian and European EMD AML trials are yet to appear.

RAC Price at posting: $1.87 Sentiment: Buy Disclosure: Held
16 Upvote

0 Great analysis

Reply

Top Stories

NVU

Nanoveu surges 10% after benchmark testing for new AI chip begins

IRX

InhaleRX snags $38.5M in funding from VC biotech funder Clendon

Week 42 Wrap: HotCopper's top picks; new ASX 200 record; world yawns at war

MTH

Mithril's drilling in Mexico picks up silver at 997g/t, gold at 28g/t

M4M

Macro, Norden set up transport solutions initiative for West Pilbara

SWP

Swoop lobs $18M offer at microcap telecom Vonex – in which it holds 19.9%

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

What's causing the cost-of-living crisis, and how to navigate it

SNX

Sierra Nevada raises $2M for silver exploration at Blackhawk

TLG

Talga Group wins key permit for flagship graphite mine in Sweden